Published in final edited form as:

Atherosclerosis. 2019 July ; 286: 172–178. doi:10.1016/j.atherosclerosis.2019.03.015.

The association between left main coronary artery calcium and cardiovascular-specific and total mortality: The Coronary Artery Calcium Consortium

Steven J. Lahti¹, David I. Feldman^{1,2}, Zeina Dardari¹, Mohammadhassan Mirbolouk¹, Olusola A. Orimoloye¹, Albert D. Osei¹, Garth Graham³, John Rumberger⁴, Leslee Shaw⁵, Matthew J Budoff⁶, Alan Rozanski⁷, Michael D. Miedema⁸, Mouaz H. Al-Mallah⁹, Dan Berman¹⁰, Khurram Nasir¹¹, and Michael J. Blaha¹

¹The Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD.

²University of Miami Miller School of Medicine, Miami, FL

³Aetna Foundation, Hartford, CT

⁴Princeton Longevity Center, Princeton, NJ

⁵Department of Radiology and Medicine, Weill Cornell Medical College, New York, NY

⁶Cardiology, Los Angeles Biomedical Research Center, Torrance, CA

⁷Department of Medicine, St. Luke's Roosevelt Hospital Center, New York, NY

⁸Minneapolis Heart Institute and Minneapolis Heart Institute Foundation,, Minneapolis, MN

⁹Houston Methodist Heart and Vascular Center, Houston, TX

¹⁰Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA

¹¹Cardiology & Center for Outcomes Research and Evaluation, Yale New Haven Hospital, Yale University, New Haven, CT

Abstract

Background and aims: Left main (LM) coronary artery disease is associated with greater myocardial infarction-related mortality, however, coronary artery calcium (CAC) scoring does not account for disease location. We explored whether LM CAC predicts excess mortality in asymptomatic adults.

Methods: Cause-specific cardiovascular and all-cause mortality was studied in 28,147 asymptomatic patients with non-zero CAC scores in the CAC Consortium. Multivariate regression

Address all correspondence to: Michael J. Blaha, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, The Johns Hopkins Hospital, Blalock 524D1, 600 N. Wolfe Street, Baltimore, MD 21287, USA, MBlaha1@jhmi.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest

The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

was performed to evaluate if the presence and burden of LM CAC predict mortality after adjustment for clinical risk factors and the Agatston CAC score. We further analyzed the per-unit hazard associated with LM CAC in comparison to CAC in other arteries.

Results: The study population had mean age of 58.3 ± 10 years and CAC score of 301 ± 631 . LM CAC was present in 21.7% of the cases. During 312,398 patient-years of follow-up, 1,907 deaths were observed. LM CAC was associated with an increased burden of clinical risk factors and total CAC, and was independently predictive of increased hazard for all-cause (HR 1.2 [1.1, 1.3]) and cardiovascular disease death (HR 1.3 [1.1, 1.5]). The hazard for death increased proportionate to the percentage of CAC localized to the LM. On a per-100 Agatston unit basis, LM CAC was associated with a 6–9% incremental hazard for death beyond knowledge of CAC in other arteries.

Conclusions: The presence and high burden of left main CAC are independently associated with a 20–30% greater hazard for cardiovascular and total mortality in asymptomatic adults, arguing that LM CAC should be routinely noted in CAC score reports when present.

Graphical Abstract

Introduction

Coronary artery calcium (CAC) detected with imaging correlates with the histopathological presence of calcified atherosclerotic plaque, providing a specific marker of subclinical coronary artery disease (CAD)¹. Quantification of CAC, as first described by Agatston et al. using non-contrast cardiac-gated computed tomography (CT),² is highly predictive of incident cardiovascular disease (CVD) events and all-cause mortality, and provides predictive value beyond that of traditional clinical risk factors^{3–6}. Accordingly, in clinical practice, CAC scans are increasingly used to stratify CVD risk in asymptomatic adults⁷.

Considering its prognostic performance, the Agatston CAC score is remarkably simple in its calculation. The Agatston CAC score is the sum of the scores of all individual calcified coronary lesions (areas with >130 Hounsfield units multiplied by a density weighting factor) visually-confirmed to be coronary calcifications under standard image acquisition parameters². A criticism of this scoring protocol is that it does not account for the potential differential risk associated with plaque localization within the coronary tree^{8–10}. For example, the Agatston method weighs CAC in the left-main (LM) coronary artery equally to that in the distal right coronary artery (RCA), despite a vast difference in the quantity of

subtended at-risk myocardium and, consequently, a faster progression from symptoms to death in patients with LM disease^{11–14}. Accordingly, it has been suggested—but not convincingly demonstrated—that LM CAC in asymptomatic patients confers incremental risk beyond that predicted by its contribution to the total CAC score¹⁵.

Limited prior data suggests a possible signal for increased risk with LM CAC. In an analysis of more than 25,000 asymptomatic adults, the Agatston score in the LM was associated with a higher relative risk for death compared to scores from the circumflex (CIRC), RCA, and left anterior descending (LAD) arteries¹⁶. In a separate study by the same authors, among vessel-specific CAC scores, only those from the LM and LAD were significantly associated with mortality after adjustment for traditional clinical risk factors¹⁷. However, because this study did not control for the total CAC score or study CVD-specific mortality, it remains unclear if LM CAC confers greater CVD-specific risk *per se* or by association with higher total CAC or other traditional risk factors.

We hypothesized that LM CAC, in a sufficiently large sample with long follow-up, confers higher risk for both CVD-specific and all-cause mortality compared to CAC in other distributions. We further hypothesized that this effect would be strongest in patients with intermediate CAC scores (1–399). To explore this possibility, we measured the burden of LM CAC among patients in the CAC Consortium, and evaluated if its presence conferred incremental cause-specific and total mortality risk to that predicted by the total Agatston CAC score and traditional cardiac risk factors.

Materials and methods

Study design

The Coronary Artery Calcium Consortium is a multi-center population-based retrospective cohort of asymptomatic patients 18 years of age, without known coronary heart disease (CHD, defined as history of MI, obstructive CAD, PCI, or CABG), who were referred for clinical CAC scoring for CVD risk stratification. The study population comprised 66,636 men and women undergoing CAC testing between 1991 and 2010. The CAC Consortium includes data from 4 different centers, each having a CAC scanning program for at least 10 years, contributing at least 5000 patients, and able to provide nearly complete individual patient-level CVD risk factor data (>90% of all fields). Informed consent was provided by all participants at the time of enrollment at each contributing center. Institutional review board approval for data coordinating center activities was obtained at the Johns Hopkins Hospital.

Study population

For the present analysis, all CAC Consortium participants with CAC>0 were considered for inclusion. In addition to the total CAC score, the presence of LM CAC and all vessel-specific contributions to the total CAC score had to be reported for each patient. This yielded a study population of 28,147 participants (76.3% of all patients with CAC>0) with complete baseline demographics and clinical characteristics.

CT data

Non-contrast cardiac-gated CT scans were performed at baseline using electron beam tomography (EBT) (93%) or multi-detector CT (MDCT) (7%), with CAC scores calculated by the Agatston method². EBT was conducted with the Imatron C-100 in 13%, C-150 in 38%, C-300 in 38%, and with the e-Speed scanner in 3.5% (GE-Imatron) of the cases. The MDCT scanners included a 4-slice device (Somatom Volume Zoom, Siemens Medical Solutions) and a 64-slice device (General Electric LightSpeed, GE Healthcare).

Risk factor data

Patient-level data on demographics, CVD risk factors, and medical history were collected by self-reports and from the electronic medical records from the initial clinical visit associated with referral for CAC testing¹⁸. Baseline information collected included hypertension (prior diagnosis or current treatment), hyperlipidemia (prior diagnosis of hyperlipidemia, dyslipidemia, use of lipid-lowering drug therapy, or laboratory data, where available), current smoking, diabetes (prior diagnosis or treatment with oral hypoglycemic agents or insulin), and family history of CHD in a first degree relative. In the 28% of cases where there was incomplete ascertainment of at least one risk marker, multiple imputation was performed using a multivariable model adjusting for age, sex, race, total CAC score, and the non-missing traditional risk factors to impute data.

Follow-up for cause-specific mortality

Ascertainment of death was determined through linkage to the Social Security Death Index using a previously validated algorithm¹⁸. Classification of death into common categories was performed by review of ICD-9 coded death certificates obtained from the National Death Index. Participants were followed for a mean of 12 ± 4 years for the incidence of CVD death or non-CVD death. All cause-death included both CVD and non-CVD mortality, with CVD mortality encompassing all CHD, as well as stroke, heart failure, and other cardiovascular mortality.

Statistical methods

Baseline demographics and clinical characteristics of the study population were analyzed in aggregate and according to LM CAC status (present or absent). Continuous data were presented as mean $\pm$ standard deviation and categorical as the total number and as proportions. The two groups defined by LM CAC status were compared using the Student's t-test and Chi-square test for continuous and categorical variables, respectively.

For descriptive purposes, the prevalence of LM CAC was calculated by CAC score group (intermediate CAC: 1–399 and elevated CAC: 400) and by number of vessels with CAC (1–4)¹⁰. These results were then presented graphically.

Absolute event rates of all-cause and cause specific death for those with LM CAC and those without LM CAC were calculated by dividing the total number of events by the total number of person-years at risk. Additionally, analyses were performed after stratifying by CAC score group. These results were then presented graphically.

To determine if the presence of LM CAC predicts time to all-cause and CVD death independently of the total Agatston CAC score, we used multivariable Cox proportional-hazards regression models. For each outcome, CAC-only adjusted and then sequentially more adjusted models were presented. Model 1 additionally adjusted for age and sex, while the fully adjusted model (Model 2) further adjusted for hyperlipidemia, smoking, hypertension, diabetes and family history. These models were then repeated after stratification by intermediate CAC (1–399) and high CAC (≥ 400).

To assess if the burden of LM CAC has predictive value beyond its qualitative presence, we constructed additional models using the following LM CAC burden cutpoints: 0% (reference), 1–25%, >25%. For these analyses, LM CAC burden was calculated by taking the CAC score in the LM and dividing by the total CAC score, expressing this quotient as a percentage.

Finally, to determine if CAC in the LM on a per Agatston unit basis was more strongly associated with adverse outcomes compared to CAC in other coronary arteries, additional regression analysis were performed entering the CAC score of each coronary artery into the model at the same time. Models were additionally adjusted for the variables from Model 2 above. The incremental predictive value of the LM CAC score (presented per 100 Agatston units) was then interpreted as the exponentiated model coefficient for LM CAC from this adjusted model (i.e. the incremental hazard ratio).

All statistical analyses were performed using STATA 14 (Stata Corp, College Station, TX). A two-tailed *p*-value of <0.05 was considered significant.

Results

Baseline characteristics

Baseline characteristics of the study population are shown in Table 1. Mean age was 58.3 ± 10 and 25% were female. Overall, LM CAC was observed in 21.7% of the asymptomatic population with CAC>0. Patients with LM CAC were more likely to have traditional CVD risk factors, including hypertension, hyperlipidemia, diabetes mellitus and smoking (*p* <0.05). They also had a higher mean CAC score (647 vs. 205) and were more likely to have CAC scores ≥ 400 (43% vs. 13%). The proportion of subjects with LM CAC involvement increased as the total CAC score and number of involved vessels increased (Fig. 1A and B).

Survival analysis by presence of LM CAC

We observed 1,907 deaths during the 312,398 patient-years of follow-up, of which 1000 (52%) were attributable to CVD, and 907 (48%) were from other causes. Fig. 2 demonstrates a graded increase in both all-cause and CVD mortality rates across CAC groups, with those with LM CAC having higher mortality rates than those with no LM CAC.

In the fully adjusted multivariate adjusted analysis, the presence of LM CAC was associated with increased hazard for all-cause death (HR 1.2 [1.1–1.3]) and CVD death (HR 1.3 [1.1–1.5]) beyond the total CAC score and traditional risk factors (Table 2 and Fig. 3).

Survival analysis by burden of LM CAC

There was a graded increase in all-cause and CVD death observed across groups with increasing LM CAC %. This trend remained statistically significant upon correction for clinical risk factors in the fully adjusted multivariate model. The hazard for all-cause and CVD death was 20% higher when the percentage of total CAC in the LM was 1–25% and 40% higher when LM CAC comprised >25% of the total. There was no difference in the hazard for all-cause as compared to CVD-specific mortality within groups with similar burden of LM CAC (Table 3).

Predictive value of LM CAC compared to CAC in other vessels

In the multivariate analysis adjusting for CAC scores in each individual coronary artery, and additionally adjusted for clinical risk factors, the incremental hazard for all-cause and CVD death was significantly higher for LM as compared to the other vessel-specific scores. Per 100 Agatston units, the incremental hazard for CVD death associated with LM CAC was 6–9% greater than that associated with the LAD, CIRC, and RCA (Table 4).

Discussion

In this large, multicenter retrospective cohort study from the CAC Consortium, we demonstrate that LM CAC is a somewhat common finding in asymptomatic patients with CAC>0 (21.7%), and is associated with more clinical CVD risk factors, higher total CAC scores, and more diffuse disease. Within individual CAC score groups, LM involvement is associated with higher crude rates of CVD and total mortality, and independently predicts a 20–30% mortality increase risk beyond the total CAC score and traditional risk factors. Moreover, per Agatston unit, the CAC score contribution from the LM leads to more increased risk than any other of the coronary arteries. Taken together, the findings suggest that LM CAC serves as a marker of a higher risk phenotype, and may be considered a modest independent risk factor for mortality beyond the traditional risk assessment and Agatston CAC scoring. These findings build on the exploratory analysis of a similar clinical cohort that demonstrated an association between LM CAC and increased all-cause mortality, despite an overall trend towards greater risk being associated with diffuse CAC¹⁵.

Much has been written about LM disease since Herrick's classic case series first described the natural history of LM coronary artery occlusion¹⁹. It is now known that acute coronary syndromes in this territory progress rapidly from the onset of symptoms and, without intervention, often culminate in massive myocardial infarction, cardiogenic shock, and sudden cardiac death²⁰. LM CAD is also a well-established prognostic factor and predictor of benefit from surgical or percutaneous revascularization in the setting of symptomatic but stable coronary artery disease^{11–14,21}. Previously, it was unknown if the high CVD risk associated with obstructive LM disease extended to asymptomatic LM CAC, which might represent its earliest clinically-recognizable manifestation.

In the most extensive prior analysis of LM CAC, Williams et al. showed that among the four coronary artery specific CAC scores, only LM and LAD appeared to be significant predictors of all-cause mortality. Likely due to differences in statistical power, here we

observe that each of the vessel-specific CAC scores, except RCA, are independent predictors of all-cause mortality, however, the greatest hazard per Agatston unit is associated with LM. The authors of the Williams et al. study also observed a particularly high mortality among patients with frequent calcifications in LM¹⁷, suggesting that LM CAC, particularly frequent discontinuous calcification, contributed a disproportionate amount of the mortality risk predicted by CAC scoring in asymptomatic populations. Correspondingly, it is demonstrated here that both LM CAC presence and burden are associated with clinical cardiovascular risk factors, higher total CAC score, and higher CVD and total mortality.

Taken together, these findings support the hypothesis that LM calcification predisposes patients to excess risk compared to its presence in other vessels and should be routinely noted in clinical CAC scoring. We hypothesize that a large portion of the excess mortality observed is related to the greater likelihood of fatal complications immediately after acute coronary events in the LM distribution, or attendant to surgical revascularization among survivors. Based on this hypothesis, it was anticipated that LM CAC would be more strongly associated with CHD as compared to all-cause mortality, however, we did not have sufficient power to detect small between-vessel differences in cause-specific mortality to all-cause mortality rate ratios. LM plaque may also serve as a marker of a more severe global atherosclerotic phenotype. For example, in asymptomatic patients who were monitored with serial coronary computed tomographic angiography (CCTA), the presence of LM disease at baseline is associated with a greater volume of high-risk plaque and its global progression within the coronary tree over time²². Therefore, the risk associated with LM CAC is likely due to progression both within the LM and in the other coronary arteries.

Our findings build on the accumulating evidence that the regional distribution of CAC significantly modifies the risk of events predicted by the Agatston method^{8,10,23}. However, if vessel-specific CAC scoring, including LM CAC, is clinically actionable remains uncertain. The findings here suggest that LM CAC is a notable high-risk finding on CAC scans that should be specifically noted on study interpretations. Further research will be needed to determine if the presence of LM CAC should be used to modify the decision to initiate risk-modifying therapy. However, based on current guidelines and evidence, the presence of LM CAC should not be used to justify unnecessary and potentially harmful stress testing or cardiac catheterization in the absence of symptoms²⁴.

The main strength of the present study is its design and size. This was a multisite cohort study with ample size to study LM-specific CAC and adjust for the total CAC score and relevant confounders. Since this is a clinical population, findings should be generalizable to practicing physicians. However, results are not necessarily generalizable to the general asymptomatic community-dwelling population, as our study may be subject to selection bias since all patients were referred by their physician for clinical CAC scoring. An additional limitation of the study is the subjective aspect of classifying CAC as residing within the left main, as experience suggests it often is contiguous with aortic, LAD, and/or circumflex calcification, and the CAC Consortium did not include core lab reading. Finally, although a post-hoc analysis was performed, we were underpowered to detect differences in risk associated with high-risk plaque features such as low density, high volume LM CAC (data not shown). Future work may be directed at determining if there are LM CAC characteristics

such as volume, density, or lesion count that can identify a subset of patients at even higher risk in need of even more aggressive therapies.

Conclusion

LM CAC is present in approximately one in five asymptomatic patients referred for clinical CAC scoring with non-zero CAC score, and LM CAC presence and burden are associated with greater mortality risk independent of the total Agatston score and clinical risk factors. LM CAC may therefore represent a high-risk phenotype that should be routinely reported on CAC scans and that may warrant close scrutiny to ensure adequate control of CVD risk.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary Artery Calcium Area by Electron-Beam Computed Tomography and Coronary Atherosclerotic Plaque Area. *Circulation*. 1995;92:2157–2162. doi:10.1161/01.CIR.92.8.2157. [PubMed: 7554196]
2. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol*. 1990;15(4):827–832. doi:10.1016/0735-1097(90)90282-T. [PubMed: 2407762]
3. Detrano R, Guerci AD, Carr JJ, et al. Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups. *N Engl J Med*. 2008;358(13):1336–1345. <http://content.nejm.org/cgi/content/abstract/358/13/1336>. [PubMed: 18367736]
4. O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. *Am J Cardiol*. 2000;85(8):945–948. doi:10.1016/S0002-9149(99)00906-6. [PubMed: 10760331]
5. Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM. Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. *Am J Cardiol*. 2000;86(5):495–498. doi:10.1016/S0002-9149(00)01000-6. [PubMed: 11009264]
6. Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. *Circulation*. 2005;112(4):572–577. doi:10.1161/CIRCULATIONAHA.104.488916. [PubMed: 16009800]
7. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk. *J Am Coll Cardiol*. 2018;72(4):434–447. doi:10.1016/j.jacc.2018.05.027. [PubMed: 30025580]
8. Alluri K, Joshi PH, Henry TS, Blumenthal RS, Nasir K, Blaha MJ. Scoring of coronary artery calcium scans: History, assumptions, current limitations, and future directions. *Atherosclerosis*. 2015;239(1):109–117. doi:10.1016/j.atherosclerosis.2014.12.040. [PubMed: 25585030]
9. Blaha MJ, Mortensen MB, Kianoush S, Tota-Maharaj R, Cainzos-Achirica M. Coronary Artery Calcium Scoring: Is It Time for a Change in Methodology? *JACC Cardiovasc Imaging*. 2017;10(8):923–937. doi:10.1016/j.jcmg.2017.05.007. [PubMed: 28797416]
10. Blaha MJ, Budoff MJ, Tota-Maharaj R, et al. Improving the CAC Score by Addition of Regional Measures of Calcium Distribution: Multi-Ethnic Study of Atherosclerosis. *JACC Cardiovasc Imaging*. 2016;9(12):1407–1416. doi:10.1016/j.jcmg.2016.03.001. [PubMed: 27085449]
11. Taylor HA, Deumite NJ, Chaitman BR, Davis KB, Killip T, Rogers WJ. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. *Circulation*. 1989;79(6):1171–1179. <http://www.ncbi.nlm.nih.gov/pubmed/2785870>. [PubMed: 2785870]

12. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. *Circulation*. 1994;89(5):2015–2025. doi:10.1161/01.CIR.89.5.2015. [PubMed: 8181125]
13. Graham MM, Faris PD, Ghali WA, et al. Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. *Am Heart J*. 2001;142(2):254–261. doi:10.1067/mhj.2001.116481. [PubMed: 11479464]
14. Min JK, Shaw LJ, Devereux RB, et al. Prognostic Value of Multidetector Coronary Computed Tomographic Angiography for Prediction of All-Cause Mortality. *J Am Coll Cardiol*. 2007;50(12):1161–1170. doi:10.1016/j.jacc.2007.03.067. [PubMed: 17868808]
15. Tota-Maharaj R, Joshi PH, Budoff MJ, et al. Usefulness of regional distribution of coronary artery calcium to improve the prediction of all-cause mortality. *Am J Cardiol*. 2015;115(9):1229–1234. doi:10.1016/j.amjcard.2015.01.555. [PubMed: 25743208]
16. Budoff MJ, Shaw LJ, Liu ST, et al. Long-Term Prognosis Associated With Coronary Calcification. Observations From a Registry of 25,253 Patients. *J Am Coll Cardiol*. 2007;49(18):1860–1870. doi:10.1016/j.jacc.2006.10.079. [PubMed: 17481445]
17. Williams M, Shaw LJ, Raggi P, et al. Prognostic Value of Number and Site of Calcified Coronary Lesions Compared With the Total Score. *JACC Cardiovasc Imaging*. 2008;1(1):61–69. doi:10.1016/j.jcmg.2007.09.001. [PubMed: 19356407]
18. Blaha MJ, Whelton SP, Al Rifai M, et al. Rationale and design of the coronary artery calcium consortium: A multicenter cohort study. *J Cardiovasc Comput Tomogr*. 2017;11(1):54–61. doi:10.1016/j.jcct.2016.11.004. [PubMed: 27884729]
19. Herrick J Clinical Features of Sudden Obstruction of the Coronary Arteries. *Jama*. 1912;59:2015–2020.
20. Rosati RA. The Prognostic Spectrum of Left Main Stenosis. 1977;(November 1969):947–953.
21. Desk R, Williams L, Health K. Survival in Subgroups of Patients with Left Main Coronary Artery Disease Veterans Administration Cooperative Study of Surgery. 1982:14–23.
22. Weir-McCall JR, Blanke P, Sellers SL, et al. Impact of Non-obstructive left main disease on the progression of coronary artery disease: A PARADIGM substudy. *J Cardiovasc Comput Tomogr*. 2018;12(3):231–237. doi:10.1016/j.jcct.2018.05.011. [PubMed: 29802032]
23. Ferencik M, Pencina KM, Liu T, et al. Coronary Artery Calcium Distribution Is an Independent Predictor of Incident Major Coronary Heart Disease Events: Results from the Framingham Heart Study. *Circ Cardiovasc Imaging*. 2017;10(10):1–9. doi:10.1161/CIRCIMAGING.117.006592.
24. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: Executive summary. *J Am Coll Cardiol*. 2010;56(25):2182–2199. doi:10.1016/j.jacc.2010.09.002.

- Left-main coronary artery calcium is present in 21% of asymptomatic patients with non-zero CAC scores
- Left-main coronary artery calcium involvement is associated with an increased burden of cardiovascular risk factors and higher total CAC scores
- Left-main coronary artery calcium is independently associated with increased hazard for all-cause and cardiovascular disease death
- Left-main coronary artery calcium is a marker of advanced coronary artery disease

A

B

Figure 1:

(A) Left main CAC prevalence by CAC score groups. (B) Left main CAC prevalence by number of coronary vessels with CAC

Abbreviations: LM, left main; CAC, coronary artery calcium

Figure 2:

Absolute mortality rates (all-cause and CVD death) per 1000 person-years, by the presence or absence of left main CAC

LM, left main; CAC, coronary artery calcium; CVD, cardiovascular disease.

Figure 3:
Hazard ratios for the association of left main CAC with the study endpoints

Table 1:

Baseline characteristics of the study population and by left main coronary artery involvement

	All N = 28,147	LMCAC not present N = 22,028	LM CAC present N = 6,119	p-value
Age (years)	58.3 ± 10	57.2 ± 10	62.2 ± 10	<i>p</i> < 0.001
Female (N, %)	7042, 25.0%	5805, 26.4%	1237, 20.2%	<i>p</i> < 0.001
Cardiovascular risk factors (N, %)				
Hypertension	10654, 38%	7865, 36%	2789, 46%	<i>p</i> < 0.001
Hyperlipidemia	17854, 63%	13677, 62%	4177, 68%	<i>p</i> < 0.001
Current smoking	2883, 10%	2205, 10%	678, 11%	<i>p</i> = 0.02
Family history of CHD	13798, 49%	10849, 48%	2949, 48%	<i>p</i> = 0.14
Diabetes mellitus	2521, 9%	1759, 8%	762, 13%	<i>p</i> < 0.001
Total CAC score				
Mean ± SD	301 ± 631	205 ± 470	647 ± 940	<i>p</i> < 0.001
Median (IQR)	73 (15,290)	49 (10, 181)	305 (88, 828)	
CAC group (N, %)				
1 – 399	22572, 80%	19088, 87%	3484, 57%	<i>p</i> < 0.001
400	5575, 20%	2940, 13%	2635, 43%	
Number of vessels with CAC (N, %)				
1	9631, 34%	9260, 42%	371, 6%	<i>p</i> < 0.011
2	7622, 27%	6809, 31%	813, 13%	
3	7434, 26%	5959, 27%	1475, 24%	
4	3460, 12%	0, 0%	3460, 57%	

LM, left main; SD, standard deviation; IQR, interquartile range; CAC, coronary artery calcium

Table 2:

Hazard ratios for the study endpoints, by presence of left main CAC

	Unadjusted	Model 1 ^a	Model 2 ^b
All-cause death			
LM CAC present	1.6 (1.5, 1.8)	1.2 (1.1, 1.4)	1.2 (1.1, 1.3)
CVD death			
LM CAC present	1.8 (1.5, 2.1)	1.3 (1.1, 1.6)	1.3 (1.1, 1.5)

All models adjusted for total CAC score on its native scale.

^aModel 1: Additionally adjusted for age and sex.

^bModel 2: Additionally adjusted for age, sex, hyperlipidemia, smoker, hypertension, diabetes, and family history

LM, left main; CAC, coronary artery calcium; CVD, cardiovascular disease

Table 3:

Hazard ratios for the association of left main CAC burden^a with the study endpoints, adjusted for total CAC score

	Unadjusted	Model 1 ^b	Model 2 ^c
All-cause death			
LM CAC 0%	1.0	1.0	1.0
LM CAC 1–24%	1.6 (1.5, 1.8)	1.2 (1.1, 1.3)	1.2 (1.04, 1.3)
LM CAC >25%	1.7 (1.4, 2.0)	1.4 (1.2, 1.7)	1.4 (1.2, 1.7)
CVD death			
LM CAC 0%	1.0	1.0	1.0
LM CAC 1–24%	1.8 (1.5, 2.2)	1.3 (1.1, 1.5)	1.2 (1.04, 1.5)
LM CAC >25%	1.6 (1.2, 2.2)	1.4 (1.04, 1.9)	1.4 (1.01, 1.9)

^aLeft main CAC burden defined as the percentage of total CAC score contributed by the left main.

^bModel 1: Adjusted for Age and Sex.

^cModel 2: Model 1 + hyperlipidemia, smoker, hypertension, diabetes, and family history

LM, left main; CAC, coronary artery calcium; CVD, cardiovascular disease

Table 4:

Incremental hazard ratios for the association of vessel-specific CAC score (per 100 Agatston units) with the study endpoints adjusted for each individual vessel CAC scores

All-cause death	
Left main score	1.1 (1.1, 1.2)
Left anterior descending score	1.03 (1.02, 1.04)
Right coronary score	1.01 (1.00, 1.02)
Left circumflex score	1.03 (1.02, 1.04)
CVD death	
Left main score	1.1 (1.09, 1.2)
left anterior descending score	1.04 (1.03, 1.05)
Right coronary score	1.01 (0.99, 1.02)
Left circumflex score	1.03 (1.01, 1.05)

Adjusted for the total CAC score of each vessel + age, sex, hyperlipidemia, smoking, hypertension, diabetes, and family history

CAC, coronary artery calcium; CVD, cardiovascular disease